

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	28	DEC 18	CA/CAplus patent kind codes updated
NEWS	29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	30	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26

FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)

H-FABP IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)

2712469 H

2568 FABP

259 FABPS

2580 FABP

(FABP OR FABPS)

319 H-FABP

(H(W) FABP)

93 HFABP

1 HFABPS

93 HFABP

(HFABP OR HFABPS)

2712469 H

2568 FABP

259 FABPS
 2580 FABP
 (FABP OR FABPS)
 319 H (W) FABP
 335556 HEART
 28346 HEARTS
 337380 HEART
 (HEART OR HEARTS)
 1745637 TYPE
 598781 TYPES
 2208661 TYPE
 (TYPE OR TYPES)
 373756 FATTY
 14 FATTIES
 373760 FATTY
 (FATTY OR FATTIES)
 4259872 ACID
 1553426 ACIDS
 4757683 ACID
 (ACID OR ACIDS)
 953897 BINDING
 2080 BINDINGS
 954489 BINDING
 (BINDING OR BINDINGS)
 1948078 PROTEIN
 1364406 PROTEINS
 2269874 PROTEIN
 (PROTEIN OR PROTEINS)
 128 HEART-TYPE FATTY ACID BINDING PROTEIN
 (HEART(W) TYPE(W) FATTY(W) ACID(W) BINDING(W) PROTEIN)
 335556 HEART
 28346 HEARTS
 337380 HEART
 (HEART OR HEARTS)
 1745637 TYPE
 598781 TYPES
 2208661 TYPE
 (TYPE OR TYPES)
 1 FACTTY
 4259872 ACID
 1553426 ACIDS
 4757683 ACID
 (ACID OR ACIDS)
 0 HEART TYPE FACTTY ACID
 (HEART(W) TYPE(W) FACTTY(W) ACID)
 953897 BINDING
 2080 BINDINGS
 954489 BINDING
 (BINDING OR BINDINGS)
 1948078 PROTEIN
 1364406 PROTEINS
 2269874 PROTEIN
 (PROTEIN OR PROTEINS)
 154312 BINDING PROTEIN
 (BINDING(W) PROTEIN)
 0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
 L1 380 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
 BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s doxorubicin or adriamycin
 15810 DOXORUBICIN
 28 DOXORUBICINS
 15812 DOXORUBICIN
 (DOXORUBICIN OR DOXORUBICINS)
 10770 ADRIAMYCIN

16 ADRIAMYCINS
10772 ADRIAMYCIN
(ADRIAMYCIN OR ADRIAMYCINS)
L2 25686 DOXORUBICIN OR ADRIAMYCIN

=> a l2 and l1

A IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and l1

L3 2 L2 AND L1

=> d ibib

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:450309 CAPLUS

DOCUMENT NUMBER: 141:36901

TITLE: Limited role of N-terminal phosphoserine residues in the activation of transcription by p53

AUTHOR(S): Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna L.; Agarwal, Archana; Stanhope-Baker, Patricia; Williams, Bryan R. G.; Stark, George R.

CORPORATE SOURCE: Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

SOURCE: Oncogene (2004), 23(25), 4477-4487

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib 1-2

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:450309 CAPLUS

DOCUMENT NUMBER: 141:36901

TITLE: Limited role of N-terminal phosphoserine residues in the activation of transcription by p53

AUTHOR(S): Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna L.; Agarwal, Archana; Stanhope-Baker, Patricia; Williams, Bryan R. G.; Stark, George R.

CORPORATE SOURCE: Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

SOURCE: Oncogene (2004), 23(25), 4477-4487

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:797013 CAPLUS

DOCUMENT NUMBER: 139:286301

TITLE: Method of judging cardiotoxicity of anthracycline-type anticancer chemical therapeutic by detecting human H-FABP and reagent therefor

INVENTOR(S): Kitayama, Hitoshi; Ohkaru, Yasuhiko

PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003083486	A1	20031009	WO 2003-JP3924	20030328
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003220882	A1	20031013	AU 2003-220882	20030328
EP 1491896	A1	20041229	EP 2003-715565	20030328
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005202513	A1	20050915	US 2004-509571	20040929
PRIORITY APPLN. INFO.:			JP 2002-93688	A 20020329
			WO 2003-JP3924	W 20030328
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> s cancer? or tumor? or neoplas?

315544 CANCER?
452001 TUMOR?
474391 NEOPLAS?

L4 748872 CANCER? OR TUMOR? OR NEOPLAS?

=> s 14 and 11

L5 32 L4 AND L1

=> s 15 not py>2002

4707679 PY>2002
L6 8 L5 NOT PY>2002

=> s 16 and antibod?

479076 ANTIBOD?

L7 2 L6 AND ANTIBOD?

=> d ibib 1-2

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:376177 CAPLUS

DOCUMENT NUMBER: 133:248010

TITLE: Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags

AUTHOR(S): Hwang, David M.; Dempsey, Adam A.; Lee, Cheuk-Yu; Liew, Choong-Chin

CORPORATE SOURCE: Cardiac Gene Unit, Department of Laboratory Medicine and Pathobiology, Centre for Cardiovascular Research, Toronto Hospital, University of Toronto, Toronto, ON, M5G 1L5, Can.

SOURCE: Genomics (2000), 66(1), 1-14
CODEN: GNMCEP; ISSN: 0888-7543

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:682528 CAPLUS
DOCUMENT NUMBER: 129:299045
TITLE: Cloning and cDNA sequence of human fatty acid-binding
protein
INVENTOR(S): Hillman, Jennifer L.; Shah, Purvi
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845440	A1	19981015	WO 1998-US7084	19980408
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868942	A	19981030	AU 1998-68942	19980408
PRIORITY APPLN. INFO.:			US 1997-825783	A2 19970408
			WO 1998-US7084	W 19980408
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> d kwic 2

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . polynucleotides which identify and encode Hu-FABP. Nucleic acids
encoding Hu-FABP were first identified in Incyte clone 2581906 from a
kidney tumor tissue cDNA library through a computer-generated
search for amino acid sequence alignments; a consensus sequence was
derived from overlapping and/or. . . acids in length and chemical and
structural homol. with FABP from chick retina, B-FABP from rat and mouse
brain, and H-FABP from mouse and human heart.
Northern anal. shows the most abundant expression of Hu-FABP in fetal
brain, which suggests a developmental role for this mol. In adults,
Hu-FABP is found primarily in cancer-associated tissues,
particularly, brain, kidney, and breast. The invention also provides
expression vectors, host cells, antibodies and antagonists. The
invention also provides methods for the prevention and treatment of
diseases associated with expression of Hu-FABP, as. . .
IT Antibodies
Probes (nucleic acid)
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical
study); BIOL (Biological study); USES (Uses)
(cloning and cDNA sequence of human fatty acid-binding protein)

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	59.03	59.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.75

-0.75

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 19 DEC 2006 <20061219/UP>
MOST RECENT UPDATE WEEK: 200650 <200650/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or
(heart type factty acid () binding protein)

485934 H
291 FABP
51 FABPS
307 FABP
(FABP OR FABPS)
45 H-FABP
(H(W) FABP)
8 HFABP
485934 H
291 FABP
51 FABPS
307 FABP
(FABP OR FABPS)
45 H (W) FABP
64305 HEART
4368 HEARTS
65049 HEART
(HEART OR HEARTS)
651740 TYPE
384590 TYPES
710359 TYPE
(TYPE OR TYPES)
75579 FATTY
2 FATTIES
75580 FATTY
(FATTY OR FATTIES)
286591 ACID
191691 ACIDS
297259 ACID
(ACID OR ACIDS)
138670 BINDING
2428 BINDINGS
139156 BINDING
(BINDING OR BINDINGS)
144350 PROTEIN
122052 PROTEINS
159658 PROTEIN
(PROTEIN OR PROTEINS)
18 HEART-TYPE FATTY ACID BINDING PROTEIN
(HEART (W) TYPE (W) FATTY (W) ACID (W) BINDING (W) PROTEIN)
64305 HEART
4368 HEARTS
65049 HEART
(HEART OR HEARTS)
651740 TYPE

384590 TYPES
710359 TYPE
 (TYPE OR TYPES)
 0 FACTTY
286591 ACID
191691 ACIDS
297259 ACID
 (ACID OR ACIDS)
 0 HEART TYPE FACTTY ACID
 (HEART(W)TYPE(W)FACTTY(W)ACID)
138670 BINDING
 2428 BINDINGS
139156 BINDING
 (BINDING OR BINDINGS)
144350 PROTEIN
122052 PROTEINS
159658 PROTEIN
 (PROTEIN OR PROTEINS)
31430 BINDING PROTEIN
 (BINDING(W)PROTEIN)
 0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
L8 57 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
 BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s 18 and antibod?

93871 ANTIBOD?

L9 41 L8 AND ANTIBOD?

=> s 19 and doxorubicin or daunomycin or anthracyclin?

1 DOXORUCICIN

3555 DAUNOMYCIN

22 DAUNOMYCINS

3565 DAUNOMYCIN

(DAUNOMYCIN OR DAUNOMYCINS)

4401 ANTHRACYCLIN?

L10 6166 L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?

=> s 19 and (doxorubicin or daunomycin or anthracyclin?)

1 DOXORUCICIN

3555 DAUNOMYCIN

22 DAUNOMYCINS

3565 DAUNOMYCIN

(DAUNOMYCIN OR DAUNOMYCINS)

4401 ANTHRACYCLIN?

L11 2 L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> d ibib 1-2

L11 ANSWER 1 OF 2
ACCESSION NUMBER: PCTFULL COPYRIGHT 2006 Univentio on STN
2006131928 PCTFULL ED 20061219 EW 200650
TITLE (ENGLISH): NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS
AND METHODS OF USE THEREOF FOR DIAGNOSIS
TITLE (FRENCH): NOUVELLES SEQUENCES DE NUCLEOTIDES ET D'ACIDES AMINES,
LEURS DOSAGES ET METHODES D'UTILISATION EN VUE DU
DIAGNOSTIC
INVENTOR(S): SAMEAH-GREENWALD, Shirley, 33/7 Arlozorov Street, 44453
Kfar-saba, IL;
NOVIK, Amit, 31 Hasayfan Street, 40600 Tel-mond, IL;
WALLACH, Shira, 40 Bnei Brit Street, 45265
Hod-hasharon, IL;
POLLOCK, Sarah, 16/2 Hoshea Street, 63506 Tel-aviv, IL;
BAZAK, Lily, 46 Raynes Street, 53461 Givatayim, IL;
TSYPKIN, Elena, 105/7 Even Gvirol Street, 64046
Tel-aviv, IL;
COJOCARU, Gad, S., 41/7 Hasayfan Street, 47248

Ramat-hasharon, IL;
 SELLA-TAVOR, Osnat, 18 Kfar Kish, 19330 Kfar Kish, IL
 PATENT ASSIGNEE(S): COMPUGEN LTD., 72 Pinchas Rosen Street, 69512 Tel Aviv, IL
 AGENT: WEBB, Cynthia et al.\$, Webb & Associates, P.O. Box 2189, 76121 Rehovot\$, IL
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2006131928	A2	20061214
W:	AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW		
RW (ARIPO):	BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2006-IL676	A	20060608
PRIORITY INFO.:	US 2005-60688320		20050608
	US 2005-60699427		20050715
	US 2005-60704414		20050802

L11 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2006026785 PCTFULL ED 20060403 EW 200610
 TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR MODULATING PGC-1a TO TREAT NEUROLOGICAL DISEASES AND DISORDERS
 TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE MODULATION DE PGC-1\$G(A) POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES NEUROLOGIQUES
 INVENTOR(S): LIN, Jiandie, 79 Chestnut Street, Apt.#1, Brookline, MA 02445, US;
 SPIEGELMAN, Bruce, M., 271 Waban Avenue, Waban, MA 02168, US
 PATENT ASSIGNEE(S): DANA-FARBER CANCER INSTITUTE, INC., 44 Binney Street, Boston, MA 02115-6084, US
 AGENT: SMITH, DeAnn, F. et al.\$, Patent Group, Foley Hoag LLP, Seaport World Trade Center West, 155 Seaport Blvd., Boston, MA 02210; 02210\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2006026785	A2	20060309
W:	AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW		
RW (ARIPO):	BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		

APPLICATION INFO.: WO 2005-US31715 A 20050906
PRIORITY INFO.: US 2004-60607412 20040903

=> d his

(FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

L1 380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2 25686 S DOXORUBICIN OR ADRIAMYCIN
L3 2 S L2 AND L1
L4 748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5 32 S L4 AND L1
L6 8 S L5 NOT PY>2002
L7 2 S L6 AND ANTIBOD?

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006

L8 57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9 41 S L8 AND ANTIBOD?
L10 6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11 2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> s 19 not py>2002

481204 PY>2002

L12 12 L9 NOT PY>2002

=> s 112 and kit

81427 KIT

38881 KITS

87623 KIT

(KIT OR KITS)

L13 9 L12 AND KIT

=> s 18/ab

16209 H/AB

16 FABP/AB

1 FABPS/AB

17 FABP/AB

((FABP OR FABPS)/AB)

6 H-FABP/AB

((H(W)FABP)/AB)

0 HFABP/AB

16209 H/AB

16 FABP/AB

1 FABPS/AB

17 FABP/AB

((FABP OR FABPS)/AB)

6 H/AB (W) FABP/AB

5057 HEART/AB

33 HEARTS/AB

5073 HEART/AB

((HEART OR HEARTS)/AB)

87567 TYPE/AB

15286 TYPES/AB

98263 TYPE/AB

((TYPE OR TYPES)/AB)

6744 FATTY/AB

63647 ACID/AB

17172 ACIDS/AB

73135 ACID/AB

((ACID OR ACIDS)/AB)

16377 BINDING/AB

141 BINDINGS/AB

16461 BINDING/AB

```

      ((BINDING OR BINDINGS)/AB)
25316 PROTEIN/AB
14190 PROTEINS/AB
34108 PROTEIN/AB
      ((PROTEIN OR PROTEINS)/AB)
      0 HEART-TYPE FATTY ACID BINDING PROTEIN/AB
      ((HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)/AB)
5057 HEART/AB
      33 HEARTS/AB
5073 HEART/AB
      ((HEART OR HEARTS)/AB)
87567 TYPE/AB
15286 TYPES/AB
98263 TYPE/AB
      ((TYPE OR TYPES)/AB)
      0 FACTTY/AB
63647 ACID/AB
17172 ACIDS/AB
73135 ACID/AB
      ((ACID OR ACIDS)/AB)
      0 HEART TYPE FACTTY ACID/AB
      ((HEART(W)TYPE(W)FACTTY(W)ACID)/AB)
16377 BINDING/AB
      141 BINDINGS/AB
16461 BINDING/AB
      ((BINDING OR BINDINGS)/AB)
25316 PROTEIN/AB
14190 PROTEINS/AB
34108 PROTEIN/AB
      ((PROTEIN OR PROTEINS)/AB)
1255 BINDING PROTEIN/AB
      ((BINDING(W)PROTEIN)/AB)
      0 HEART TYPE FACTTY ACID/AB (W) BINDING PROTEIN/AB
L14      6 (H-FABP/AB OR (HFABP/AB) OR (H/AB (W) FABP/AB) OR (HEART-TYPE
      FATTY ACID BINDING PROTEIN/AB) OR (HEART TYPE FACTTY ACID/AB
      (W) BINDING PROTEIN/AB))

```

=> s 18/clm

```

190960 H/CLM
      60 FABP/CLM
      14 H-FABP/CLM
      ((H(W)FABP)/CLM)
      1 HFABP/CLM
190960 H/CLM
      60 FABP/CLM
      14 H/CLM (W) FABP/CLM
11386 HEART/CLM
104803 TYPE/CLM
14215 FATTY/CLM
136223 ACID/CLM
40435 BINDING/CLM
52853 PROTEIN/CLM
      6 HEART-TYPE FATTY ACID BINDING PROTEIN/CLM
      ((HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)/CLM)
11386 HEART/CLM
104803 TYPE/CLM
      0 FACTTY/CLM
136223 ACID/CLM
      0 HEART TYPE FACTTY ACID/CLM
      ((HEART(W)TYPE(W)FACTTY(W)ACID)/CLM)
40435 BINDING/CLM
52853 PROTEIN/CLM
3331 BINDING PROTEIN/CLM
      ((BINDING(W)PROTEIN)/CLM)
      0 HEART TYPE FACTTY ACID/CLM (W) BINDING PROTEIN/CLM

```

L15 17 (H-FABP/CLM OR (HFABP/CLM) OR (H/CLM (W) FABP/CLM) OR (HEART-TYP
E FATTY ACID BINDING PROTEIN/CLM) OR (HEART TYPE FACTTY ACID/CLM
(W) BINDING PROTEIN/CLM))

=> s l15 or l14

L16 19 L15 OR L14

=> d his

(FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

L1 380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2 25686 S DOXORUBICIN OR ADRIAMYCIN
L3 2 S L2 AND L1
L4 748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5 32 S L4 AND L1
L6 8 S L5 NOT PY>2002
L7 2 S L6 AND ANTIBOD?

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006

L8 57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9 41 S L8 AND ANTIBOD?
L10 6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11 2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
L12 12 S L9 NOT PY>2002
L13 9 S L12 AND KIT
L14 6 S L8/AB
L15 17 S L8/CLM
L16 19 S L15 OR L14

=> s l16 and l13

L17 3 L16 AND L13

=> d ibib 1-3

L17 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002089657 PCTFULL ED 20021121 EW 200246
TITLE (ENGLISH): DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND
METHODS OF USE THEREOF
TITLE (FRENCH): MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS
ET LEURS METHODES D'UTILISATION
INVENTOR(S): VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US];
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US];
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US];
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US]
PATENT ASSIGNEE(S): BIOSITE, INC., 11030 Roselle Street, San Diego, CA
92121, US [US, US], for all designates States except
US;
VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US], for US only;
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US], for US only;
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US], for US only;
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US], for US only
AGENT: WARBURG, Richard, J.\$, Foley & Lardner, P.O. Box 80278,
San Diego, CA 92138-0278\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English

DOCUMENT TYPE:
PATENT INFORMATION:

Patent

NUMBER KIND DATE

WO 2002089657 A2 20021114

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-US14219 A 20020504

PRIORITY INFO.:

US 2001-60/288,871 20010504

US 2001-60/315,642 20010828

L17 ANSWER 2 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

2001067108 PCTFULL

no bibliographic data available - please use FPI for PI information

DESIGNATED STATES

L17 ANSWER 3 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

1997035878 PCTFULL ED 20020514

TITLE (ENGLISH):

THE PORCINE HEART FATTY ACID-BINDING PROTEIN ENCODING
GENE AND METHODS TO IDENTIFY POLYMORPHISMS ASSOCIATED
WITH BODY WEIGHT

TITLE (FRENCH):

GENE CODANT UNE PROTEINE SE LIANT A UN ACIDE GRAS DU
COEUR DE PORC ET PROCEDE D'IDENTIFICATION DES
CARACTERISTIQUES DU POLYMORPHISME RESPONSABLES DU POIDS
DU CORPS

INVENTOR(S):

GERBENS, Frans

PATENT ASSIGNEE(S):

DALLAND B.V.;

PROVA B.V.;

STAMBOEK ZUID B.V.;

NOORD NEDERLANDS VARKENSSTAMBOEK B.V.;

INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID (ID-DLO);

GERBENS, Frans

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER KIND DATE

WO 9735878 A2 19971002

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ
UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG

APPLICATION INFO.:

WO 1997-NL157 A 19970327

PRIORITY INFO.:

NL 1996-96200855.3 19960328

=> d ibib kwic 1

L17 ANSWER 1 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

2002089657 PCTFULL ED 20021121 EW 200246

TITLE (ENGLISH):

DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND
METHODS OF USE THEREOF

TITLE (FRENCH): MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS
ET LEURS METHODES D'UTILISATION

INVENTOR(S): VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US];
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US];
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US];
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US]

PATENT ASSIGNEE(S): BIOSITE, INC., 11030 Roselle Street, San Diego, CA
92121, US [US, US], for all designates States except
US;
VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US], for US only;
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US], for US only;
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US], for US only;
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US], for US only

AGENT: WARBURG, Richard, J.\$, Foley & Lardner, P.O. Box 80278,
San Diego, CA 92138-0278\$, US

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2002089657	A2	20021114
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US14219	A	20020504
PRIORITY INFO.:	US 2001-60/288,871		20010504
	US 2001-60/315,642		20010828

DETD annexin V, B-type natriuretic peptide, P-enolase,
cardiac troponin I (free and/or complexed), cardiac troponin T (free
and/or coincomplexed),
creatine kinase-MB, glycogen phosphorylase-BB, heart-
type fatty acid binding
protein,
phosphoglyceric acid mutase-MB, and S-100ao. These specific markers are
described
in detail hereinafter.

[00381 In a further aspect, the invention relates to kits for
determining the diagnosis
or prognosis of a patient. These kits preferably comprise
devices and reagents for
measuring one or more marker levels in a patient sample, and
instructions for
performing the assay. Optionally, the kits may contain one or
more means for
converting marker level(s) to a prognosis. Such kits
preferably contain sufficient

reagents to perform one or more such determinations.

al., *Ain. J. Einerg. Med* 17:225-229, 1999). This apparent non-specificity may be related to the quality and specificity of the antibodies used in the immunoassay. cTnI is released into the bloodstream following cardiac cell death. The plasma concentration of cTnI in patients with.

[00591 Heart-type fatty acid binding protein (H-FABP) is a cytosolic 15 kDa lipid-binding protein involved in lipid metabolism. Heart-type FABP antigen is found not only in heart tissue,. . . and Maatman, R.G., *Prog. Lipid Res.* 34:17-52, 1995). The normal plasma concentration of FABP is < 6 ng/ml (400 pM). The plasma H-FABP concentration is elevated in patients with AMI and unstable angina (Ishii, J. et al., *Clin. Chem.* 43:1372-1378, 1997; Tsuji, R. et al., *Int. J Cardiol.* 41:209-217, 1993). Furthermore, H-FABP may be useful in estimating infarct size in patients with AMI (Glatz, U. et al., *Br.*

Heart J. 71:135-140, 1994). Myocardial tissue as a source of H-FABP can be confirmed by determining the ratio of myoglobin/FABP (grams/grams). A ratio of approximately 5 indicates that FABP is of myocardial origin,. . . while a higher ratio indicates skeletal muscle sources (Van Nieuwenhoven, F.A. et al., *Circulation* 92:2848-2854, 1995). Because of the presence of H-FABP in skeletal muscle, kidney and brain, elevations in the plasma H-FABP concentration may be associated with skeletal muscle injury, renal disease, or stroke. H-FABP is released into the bloodstream following cardiac tissue necrosis. The plasma H-FABP concentration can be significantly elevated 1-2 hours after the onset of chest pain, earlier than CK-MB and myoglobin (Tsuji, R. et al.,. . .

Additionally, H-FABP is rapidly cleared from the bloodstream, and plasma concentrations return to baseline after 24 hours after AMI onset (Glatz, J.F. et. . .

mediate crosslinking of platelets to vascular subendothelium, respectively. Measurement of any of these vWF forms, when used in an assay that employs antibodies specific for the protease cleavage domain may allow assays to be used to determine the circulating concentration of various vWF forms in.

TpPTM may also be useful in determining the severity of unstable angina. American Biogenetic Sciences, Inc. instructs users of the TpPTM ELISA assay kit to collect blood using citrate as an anticoagulant, and they recommend against using EDTA. The effect of the anticoagulant used during.

in the art (for example, the measurement of marker RNA levels). The presence or amount of a marker is generally determined using antibodies specific for each marker and detecting specific binding. Any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like. Specific immunological binding of the antibody to the marker can be detected directly or indirectly. Direct labels include fluorescent or luminescent tags, metals, dyes, radionuclides, and the like, attached to the antibody. Indirect labels include various enzymes well known in the art, such as alkaline phosphatase, horseradish peroxidase and the like.

[00981 The use of immobilized antibodies specific for the markers is also contemplated by the present invention. The antibodies could be immobilized onto a variety of solid supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate. . . . of a solid substrate material (such as plastic, nylon, paper), and the like. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip
55
could then be dipped into the test sample and then processed quickly through. . . .

[01021 In another embodiment, the present invention provides a kit for the analysis of markers. Such a kit preferably comprises devices and reagents for the analysis of at least one test sample and instructions for performing the assay. Optionally the kits may contain one or more means for converting a marker level to a diagnosis or prognosis of
I O the patient.

[01041 Markers were measured using standard immunoassay techniques. These techniques involved the use of antibodies to specifically bind the protein targets. A monoclonal antibody directed against a selected marker was biotinylated using N-hydroxysuccinimide biotin (NHS-biotin) at a ratio of about 5 NHS-biotin moieties per antibody. The antibody-biotin conjugate was then added to wells of a standard avidin 384 well microtiter plate, and antibody conjugate not bound to the plate was removed. This formed the anti-marker in the microtiter plate. Another monoclonal
57

antibody directed against the same marker was conjugated to alkaline phosphatase using succinimidyl 4-[N-maleimidomethyl]-cyclohexane-1-carboxylate (SMCC) and N-succinimidyl 3-[2-pyridyldithio]propionate (SPDP) (Pierce, . . .

[01051 Immunoassays were performed on a TECAN Genesis RSP 200/8 Workstation. Biotinylated antibodies were pipetted into microtiter plate wells previously coated with avidin and incubated for 60 min. The solution containing unbound antibody was removed, and the cells were washed with a wash buffer, consisting of 20 mM borate (pH 7.42) containing 150 mM NaCl, and incubated for 60 min. The sample was then removed and the wells were washed with a wash buffer. The antibody-alkaline phosphatase conjugate was then added to the wells and incubated for an additional 60 min, after which time, the antibody conjugate was removed and the wells were washed with a wash buffer. A substrate, (AttoPhos), Promega, Madison, WI) was added to. . .

[01061 Assays for BNP were performed using murine anti-BNP monoclonal antibody 106.3 obtained from Scios Incorporated (Sunnyvale, CA). The hybridoma cell line secreting mAb 106.3 was generated from a fusion between FOXP-3 cells and spleen cells from a Balb/c mouse immunized with human BNP 1-32 conjugated to BSA. A second murine anti-BNP antibody was produced by Biosite Incorporated (San Diego, CA) by antibody phage display as described previously (US Patent No.

[01071 Assays for MMP-9 were performed using murine anti-MMP-9 antibodies generated by Biosite Incorporated using phage display and recombinant protein expression as described previously (US Patent No. 6,057,098). Commercially available MMP-9 antigen was used for assay standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The immunogen used for antibody production was prepared by Biosite Incorporated. PCR primers were made corresponding to sequence at the 5'-end of human MMP-9 and the coding. . .

of these clones (A4MMP9peak12) was verified at MacConnell Research (San Diego, CA) by the dideoxy chain termination method using a Sequatherm sequencing

kit (Epicenter Technologies, Madison, WI), oligonucleotide primers C, 5'-

TTCTCAAGCCTCAGACAGTG - Y (SEQ ID NO:3), and D, 5'-

CCTGGATGCAGGCTACTCTAG - Y (SEQ ID NO:4), that. . . suitable for transfection and the subsequent

expression and purification of human MMP-9 was prepared from clone MMP9peak12.2 using an EndoFree Plasmid Mega Kit as per manufacturer's

recommendations (Qiagen, Valencia, CA). HEK 293 (Peak) cells were expanded into

a T-75 flask from a 1ml frozen vial. . .

[01081 Assays for NUVIP-9 were performed using murine anti-XIMP-9 antibodies generated at Biosite Incorporated, using phage display and recombinant protein expression techniques. Commercially available NIMP-9 antigen was used for assay

standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The concentration of MMP-9 was quantified by detecting the binding of alkaline phosphatase-conjugated antibody. The minimal detectable concentration for the assay was 0.3 ng/mL and the upper end of the reportable range was 2000 ng/mL.

[01091 Assays for Thrombus precursor Protein (TpPTM) were performed using reagents obtained from American Biogenetic Sciences, Inc., Columbia,]M-Two murine monoclonal antibodies that recognize different epitopes on the soluble fibrin polymer were employed for the assay. The assay was calibrated using TpPTM supplied by.

[01101 Assays for Monocyte Chemotactic protein-1 (MCP-1) were performed using antibodies developed at Biosite. The assays were developed in an immunometric (sandwich) format. The assays were calibrated with an in-house MCP- I.

various forms of troponin I (TIC complex and total TnI) were performed using a commercially available goat anti-TnI for capture and antibodies developed at Biosite as the enzyme-labeled conjugates. The assays were calibrated with in-house TIC complex and TnI reference solutions. The minimal detectable concentration.

[0112] Assays for fatty acid binding protein (FABP) were performed using commercially available monoclonal antibodies and a commercially available FABP antigen. The minimal detectable concentration was 6 ng/ml and the upper end of the reportable range was.

in the example above. Alternative or additional markers of myocardial injury include annexin V, BNP and/or BNP-related peptides, P-enolase, creatine kinase-MB, glycogen phosphorylase-BB, heart-type fatty acid binding protein, phosphoglyceric acid mutase-MB, and S-100ao.

MMP-9 assay

[01241 Assays for MAV-9 were performed using murine anti-MMP-9 antibodies generated at Biosite Incorporated, using phage display and recombinant protein expression techniques. Commercially available NEVIP-9 antigen was used for assay standardization (Calbiochem-Novabiochem Corporation,. . . on a robotic high-throughput platform (TECAN Genesis RSP 200/8). The concentration of MMP-9 was quantified by detecting the binding of alkaline phosphatase-conjugated antibody. All samples were run in duplicate. The minimal detectable concentration for the assay was 3.0 ng/mL and the upper end of the.

strategies can include, e.g., delivery of antisense compositions in order to disrupt the synthesis of NWP-9; delivery of receptor-based therapeutics (e.g., an antibody composition directed to MMP-9 or a fragment thereof); and/or delivery of small molecule therapeutics (e.g., heparin can decrease MMP-9 synthesis, tetracycline antibiotics. . .

CLMEN. . . myocardial injury is selected from the group consisting of annexin V, B-type natriuretic peptide, enolase, cardiac troponin I, creatine kinase-MB, glycogen phosphorylase-BB, heart-type fatty acid binding protein, phosphoglyceric acid mutase-MB, and S- 1 00ao.

=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or (daunomycin or daunorubicin)

188048 ANTI
185 ANTIS
188087 ANTI
(ANTI OR ANTIS)
79510 CANCER
30806 CANCERS
81924 CANCER
(CANCER OR CANCERS)
12783 ANTI (W) CANCER
35587 CHEMOTHE?
4414 ANTHRACYCL?
18658 DOX?
5135 ADRIAMYCIN
17 ADRIAMYCINS
5142 ADRIAMYCIN
(ADRIAMYCIN OR ADRIAMYCINS)
3555 DAUNOMYCIN
22 DAUNOMYCINS
3565 DAUNOMYCIN
(DAUNOMYCIN OR DAUNOMYCINS)
6682 DAUNORUBICIN
12 DAUNORUBICINS
6684 DAUNORUBICIN
(DAUNORUBICIN OR DAUNORUBICINS)

L18 49281 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> d his

(FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

L1 380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2 25686 S DOXORUBICIN OR ADRIAMYCIN
L3 2 S L2 AND L1
L4 748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5 32 S L4 AND L1
L6 8 S L5 NOT PY>2002
L7 2 S L6 AND ANTIBOD?

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006

L8 57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9 41 S L8 AND ANTIBOD?
L10 6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?

L11 2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
 L12 12 S L9 NOT PY>2002
 L13 9 S L12 AND KIT
 L14 6 S L8/AB
 L15 17 S L8/CLM
 L16 19 S L15 OR L14
 L17 3 S L16 AND L13
 L18 49281 S (ANTI () CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR

=> s l18 and l17

L19 0 L18 AND L17

=> s l19 and l9

L20 0 L19 AND L9

=> s l18 and l9

L21 8 L18 AND L9

=> s l21 not py>2002

481204 PY>2002

L22 3 L21 NOT PY>2002

=> d ibib 1-3

L22 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2001068851 PCTFULL ED 20020822
 TITLE (ENGLISH): POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
 TITLE (FRENCH): NOUVEAUX POLYPEPTIDES ET ACIDES NUCLEIQUES LES CODANT
 INVENTOR(S): PADIGARU, Muralidhara;
 VERNET, Corine, A., M.;
 FERNANDES, Elma;
 SHIMKETS, Richard, A.;
 SPADERNA, Steven, K.;
 MAJUMDER, Kumud;
 LI, Li
 PATENT ASSIGNEE(S): CURAGEN CORPORATION;
 PADIGARU, Muralidhara;
 VERNET, Corine, A., M.;
 FERNANDES, Elma;
 SHIMKETS, Richard, A.;
 SPADERNA, Steven, K.;
 MAJUMDER, Kumud;
 LI, Li
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001068851	A2	20010920

DESIGNATED STATES
 W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
 IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
 MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
 SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
 CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
 CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US7735 A 20010312

PRIORITY INFO.:
 US 2000-60/188,316 20000310
 US 2000-60/188,277 20000310
 US 2000-60/189,139 20000314
 US 2000-60/189,140 20000314
 US 2000-60/190,401 20000317
 US 2000-60/190,231 20000317

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2000033083 PCTFULL ED 20020515
 TITLE (ENGLISH): DIAGNOSIS OF STAGE OR AGGRESSIVENESS OF CANCER
 TITLE (FRENCH): DIAGNOSTIC DE LA PHASE D'EVOLUTION OU DE L'AGRESSIVITE
 DE CANCERS
 INVENTOR(S): JETT, Marti;
 DAS, Rina;
 NEILL, Roger
 PATENT ASSIGNEE(S): WRAIR;
 JETT, Marti;
 DAS, Rina;
 NEILL, Roger
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000033083	A1	20000608

DESIGNATED STATES
 W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
 KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
 GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
 ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US28314 A 19991130
 PRIORITY INFO.: US 1998-60/110,484 19981201

L22 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1997035028 PCTFULL ED 20020514
 TITLE (ENGLISH): CYTOSTATIN III
 TITLE (FRENCH): CYTOSTATINE III
 INVENTOR(S): NI, Jian;
 YU, Guo-Liang;
 GENTZ, Reiner, L.
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
 NI, Jian;
 YU, Guo-Liang;
 GENTZ, Reiner, L.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9735028	A1	19970925

DESIGNATED STATES
 W:

AM AU BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LT
 LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM UA US UZ VN
 AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1996-US3697 A 19960319

=> d kwic 2

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD BACKGROUND OF THE INVENTION

Although screening mammography and the increased use of breast
 conserving surgery
 and adjuvant chemotherapy have improved the quality of life
 and prolonged survival for women
 with breast cancer, additional therapeutic strategies are needed to
 combat.

Modulation of mitogenesis by liver fatty acid binding protein, Cancer Metastasis Rev 13:317-36, 1994.). In contrast, MDGI (H-FABP) appears only in normal and not tumor mammary cells (Grosse R, Boehmer FD, Langen P, Kurtz A, Lehmann W, Mieth M. . .

types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1081:1-24, 1991). L-FABP exhibits different lipid binding characteristics from that of A-FABP or H-FABP. L-FABP transfected into rat hepatoma cells also mediates cell induction by carcinogenic peroxisome proliferators (Khan SH and Sorof S.: Liver. . .

L-FABP is elevated significantly in metastatic or regenerating liver vs normal liver. This is in stark contrast to H-FABP, also known as mammary derived growth inhibitor (MDGI). It is present only in normal lactating breast, and completely disappears in mammary. . . performed a similar study (to the eicosanoid generation in hepatic cells) in MCF-7 cells transfected with a clone of the MDGI (H-FABP) gene or vector alone. The inventors also have examined these pairs of cells to determine cell cycle pattern changes related to MDGI. . .

identification of markers that define their degree of differentiation. Cancer Res 57:4111-7, 1997.). Although FABPs are intracellular proteins, H-FABP has been detected in elevated levels in plasma and urine of patients suffering from myocardial infarction, (Sohmiya K, Tanaka T, Tsuji R, . . . III had 37% reduction and grade IV had no A-FABP expression. A-FABP may act as a growth inhibitor similar to the MDGI (H-FABP) protein in breast cancer and loss of A-FABP expression may serve as a prognostic marker for aggressive bladder cancer.

These results suggests that A-FAIBP and E-FA_BP may act as a tumor suppressors in prostate cells similar to MDGI (H-FABP) in MCF-7 cells (Huynh H, Alpert L and Pollak M..

fluid but normal prostate cells did not secrete measurable amounts of this protein. In addition, previous studies have shown that a) H-FABP was secreted into plasma during severe myocardial infarction and b) E-FABP was decreased in urine in bladder cancer.

The inventors have shown that the pattern of B-, L-, I-FABPs, taken together, along with decreases in A-, E-, and H-FABPs, are indicative of the relative aggressiveness of the cancer. The pattern of FABI's provide potential markers to help patients choose a.

Furthermore, the normal cell-associated FABPs (E-, A-, and H-FABPs) were decreased in tumor cells (3 -II fold). In patient specimens of normal and tumor prostate tissue, these patterns were repeated, in. . .

sample was used by doing a concentration curve for each sample. These biotin labeled PCR products were quantitated using streptavidin coated antibodies (Streptavidin has very high affinity for Biotin) which was linked to HRP (Horse Radish Peroxidase) or a fluorescent tag that was used. . . .

(Bradford method, Bio Rad, CA) and then ELISA was performed to evaluate the levels of the various FABI's by using specific antibodies to each of the different types of FABPs. Antibodies such as heart FABP antibody and Liver-FABP antibody obtained from Research Diagnostics, Inc., Pleasant Hill Road, Flanders, NJ 07836 were used in these tests. However, antibodies for the remaining FABPS can also be developed and used. The levels of these proteins were correlated to the stages of. . . .

4) epidermis or psoriasis-associated (E-FABP), 5) liver (L-FABP), 6) intestine (I-FABP), and 7) myelin or P2 (P2-FABP). As a group A-FABP, H-FABP, B-FABP, and E-FABP in humans share between 50-65% protein sequence homology and contain a tyrosine near residue 20 that can be. . . .

MCF-7 ADR cells. This allows the use of this drug when the patient starts showing drug resistance to the commonly used chemotherapeutic drugs. This drug is nontoxic to mice when tested for any change in body weight or by necropsy studies. This drug is also not toxic to human bone marrow cells, which are effected the most during chemotherapy.

inhibitors of eicosanoid metabolism on the growth of breast cancer cells. Inhibitors contemplated are those currently used in clinical situations such as doxorubicin, 5FU, vinca alkaloids, adriamycin as well as lipoxygenase inhibitors. The HPA drug can be given simultaneously with or can be given followed by exposing the cancerous. . . . to block the growth of the cancerous cells and change the FABP profile to a normal cell FABP profile. Subsequent

27 applications of chemotherapeutic agents or inhibitor can be given in a lower amount than previous applications.

representing unique regions of each specific FABP. We will synthesize these peptides, attach them to a carrier molecule and generate specific antibodies for each of FABPs. These

30 antibodies are crucial for use in development of ELISA procedures to detect each of the specific FABI's in body fluids and, perhaps,. . . .

CLMEN. . . . 8 The method of claim 4, wherein said detecting comprises measuring the amount fatty acid binding proteins in the sample with antibodies and determining type of fatty acid binding protein in the sample by ELISA.

9 The method of claim 5, wherein said detecting comprises measuring the amount fatty

acid binding proteins in the sample with antibodies and determining type of fatty acid binding protein in the sample by ELISA.

10 The method of claim 8, wherein said antibodies are specific to at least one protein selected from the group consisting of Liver-FABP, Intestinal-FABP, Adipose-FABP, CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

11 The method of claim 9, wherein said antibodies are specific to at least one protein selected from the group consisting of Liver-FABP, Intestinal-FABP, Adipose-FABP, CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

of-
a) detecting the amount of at least one fatty acid binding protein present in a sample of mammalian body fluid with antibodies specific to said fatty acid binding protein;
b) determining the difference in the amount of the at least one fatty acid binding protein.

the
steps of-
a) detecting the amount of at least one fatty acid binding protein present in a sample of mammalian tissue with antibodies specific to said fatty acid binding protein;
39
b) detennining the difference in the amount of the at least one fatty acid.

cell
FABP profile to a normal cell FABP profile; and
b) exposing the cancer cells to a first predetermined amount of a chemotherapeutic agent or cancer inhibitor sufficient to block the growth of the cells.

21 The method of claim 19, wherein said inhibitor is doxorubicin, 5FU, vinca alkaloids or lipoxxygenase inhibitors.

26 The method of inhibiting growth of cancer cells of claim 19, further comprising exposing the cancer cells to a chemotherapeutic agent or inhibitor a second time in a second lower amount than said first predetermined amount.

of breast or. prostate cancer cells of claim 19, wherein the method of inhibiting directed to breast cells and the known chemotherapeutic agent or drug is one of 5-flourouracil or adriamycin.

=> file dissab
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
33.07	92.31

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00

-0.75

FILE 'DISSABS' ENTERED AT 11:39:16 ON 19 DEC 2006

COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE COVERS 1861 TO 27 NOV 2006 (20061127/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)

59809 H
95 FABP
29 FABPS
102 FABP
(FABP OR FABPS)
13 H-FABP
(H(W) FABP)
1 HFABP
59809 H
95 FABP
29 FABPS
102 FABP
(FABP OR FABPS)
13 H (W) FABP
19262 HEART
1651 HEARTS
20021 HEART
(HEART OR HEARTS)
138410 TYPE
97741 TYPES
211295 TYPE
(TYPE OR TYPES)
7556 FATTY
1 FATTIES
7557 FATTY
(FATTY OR FATTIES)
68494 ACID
24901 ACIDS
80503 ACID
(ACID OR ACIDS)
49720 BINDING
166 BINDINGS
49793 BINDING
(BINDING OR BINDINGS)
80601 PROTEIN
44527 PROTEINS
93270 PROTEIN
(PROTEIN OR PROTEINS)
3 HEART-TYPE FATTY ACID BINDING PROTEIN
(HEART (W) TYPE (W) FATTY (W) ACID (W) BINDING (W) PROTEIN)
19262 HEART
1651 HEARTS
20021 HEART
(HEART OR HEARTS)
138410 TYPE
97741 TYPES
211295 TYPE

(TYPE OR TYPES)
 0 FACTTY
 68494 ACID
 24901 ACIDS
 80503 ACID
 (ACID OR ACIDS)
 0 HEART TYPE FACTTY ACID
 (HEART(W) TYPE(W) FACTTY(W) ACID)
 49720 BINDING
 166 BINDINGS
 49793 BINDING
 (BINDING OR BINDINGS)
 80601 PROTEIN
 44527 PROTEINS
 93270 PROTEIN
 (PROTEIN OR PROTEINS)
 7721 BINDING PROTEIN
 (BINDING(W) PROTEIN)
 0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
 L23 15 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
 BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s 123 and antibod?
 19910 ANTIBOD?
 L24 3 L23 AND ANTIBOD?
 => d ibib 1-3

L24 ANSWER 1 OF 3 DISSABS COPYRIGHT (C) 2006 ProQuest Information and
 Learning Company; All Rights Reserved on STN
 ACCESSION NUMBER: 2001:30986 DISSABS Order Number: AAI9991903
 TITLE: Mechanisms of fatty acid transport and uptake by adipocyte
 fatty acid-binding protein
 AUTHOR: Liou, Heng-Ling [Ph.D.]; Storch, Judith [adviser]
 CORPORATE SOURCE: Rutgers The State University of New Jersey - New Brunswick
 (0190)
 SOURCE: Dissertation Abstracts International, (2000) Vol. 61, No.
 10B, p. 5242. Order No.: AAI9991903. 251 pages.
 ISBN: 0-599-99576-9.
 DOCUMENT TYPE: Dissertation
 FILE SEGMENT: DAI
 LANGUAGE: English

L24 ANSWER 2 OF 3 DISSABS COPYRIGHT (C) 2006 ProQuest Information and
 Learning Company; All Rights Reserved on STN
 ACCESSION NUMBER: 97:77250 DISSABS Order Number: AAR9800797
 TITLE: STRUCTURE, FUNCTION AND DISTRIBUTION OF LIPID BINDING
 PROTEINS IN MOUSE BRAIN (HEART FATTY ACID BINDING PROTEIN,
 AGING)
 AUTHOR: PU, LIXIA [PH.D.]; SCHROEDER, FRIEDHELM [advisor]
 CORPORATE SOURCE: TEXAS A&M UNIVERSITY (0803)
 SOURCE: Dissertation Abstracts International, (1997) Vol. 58, No.
 7B, p. 3597. Order No.: AAR9800797. 147 pages.
 DOCUMENT TYPE: Dissertation
 FILE SEGMENT: DAI
 LANGUAGE: English
 ENTRY DATE: Entered STN: 19971124
 Last Updated on STN: 19971124

L24 ANSWER 3 OF 3 DISSABS COPYRIGHT (C) 2006 ProQuest Information and
 Learning Company; All Rights Reserved on STN
 ACCESSION NUMBER: 94:22128 DISSABS Order Number: AARC349190 (not available
 for sale by UMI)
 TITLE: HETEROLOGOUS EXPRESSION OF THE BOVINE CARDIAC FATTY
 ACID-BINDING PROTEIN (H-FABP) IN THE

YEAST YARROWIA LIPOLYTICA: BIOCHEMICAL AND PHYSIOLOGICAL
STUDIES
HETEROLOGE EXPRESSION DES FETTSÄURE-BINDENDEN PROTEINS AUS
RINDERHERZ (H-FABP) IN DER HEFE
YARROWIA LIPOLYTICA: BIOCHEMISCHE UND PHYSIOLOGISCHE
UNTERSUCHUNGEN

AUTHOR: BAUER, RONALD EDUARD [DR. TECHN.]
CORPORATE SOURCE: TECHNISCHE UNIVERSITÄT GRAZ (AUSTRIA) (5800)
SOURCE: Dissertation Abstracts International, (1993) Vol. 55, No.
2C, p. 449. Order No.: AARC349190 (not available for sale
by UMI). UNIVERSITY LIBRARY, TECHNISCHE UNIVERSITÄT GRAZ,
TECHNIKERSTRASSE 4, A-8010 GRAZ, AUSTRIA.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: German
ENTRY DATE: Entered STN: 19940607
Last Updated on STN: 19940607

=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or
(daunomycin or daunorubicin)

27176 ANTI
10 ANTIS
27182 ANTI
(ANTI OR ANTIS)
15632 CANCER
2379 CANCERS
16412 CANCER
(CANCER OR CANCERS)
488 ANTI (W) CANCER
2780 CHEMOTHE?
247 ANTHRACYCL?
825 DOX?
257 ADRIAMYCIN
92 DAUNOMYCIN
1 DAUNOMYCINS
92 DAUNOMYCIN
(DAUNOMYCIN OR DAUNOMYCINS)
78 DAUNORUBICIN

L25 4221 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR
ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> s 124 and 125

L26 0 L24 AND L25

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.57	96.88

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.75

CA SUBSCRIBER PRICE

STN. INTERNATIONAL LOGOFF AT 11:40:15 ON 19 DEC 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	28	DEC 18	CA/CAplus patent kind codes updated
NEWS	29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	30	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26

FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)

H-FABP IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)

2712469 H

2568 FABP

259 FABPS

2580 FABP

(FABP OR FABPS)

319 H-FABP

(H(W) FABP)

93 HFABP

1 HFABPS

93 HFABP

(HFABP OR HFABPS)

2712469 H

2568 FABP

259 FABPS
 2580 FABP
 (FABP OR FABPS)
 319 H (W) FABP
 335556 HEART
 28346 HEARTS
 337380 HEART
 (HEART OR HEARTS)
 1745637 TYPE
 598781 TYPES
 2208661 TYPE
 (TYPE OR TYPES)
 373756 FATTY
 14 FATTIES
 373760 FATTY
 (FATTY OR FATTIES)
 4259872 ACID
 1553426 ACIDS
 4757683 ACID
 (ACID OR ACIDS)
 953897 BINDING
 2080 BINDINGS
 954489 BINDING
 (BINDING OR BINDINGS)
 1948078 PROTEIN
 1364406 PROTEINS
 2269874 PROTEIN
 (PROTEIN OR PROTEINS)
 128 HEART-TYPE FATTY ACID BINDING PROTEIN
 (HEART (W) TYPE (W) FATTY (W) ACID (W) BINDING (W) PROTEIN)
 335556 HEART
 28346 HEARTS
 337380 HEART
 (HEART OR HEARTS)
 1745637 TYPE
 598781 TYPES
 2208661 TYPE
 (TYPE OR TYPES)
 1 FACTTY
 4259872 ACID
 1553426 ACIDS
 4757683 ACID
 (ACID OR ACIDS)
 0 HEART TYPE FACTTY ACID
 (HEART (W) TYPE (W) FACTTY (W) ACID)
 953897 BINDING
 2080 BINDINGS
 954489 BINDING
 (BINDING OR BINDINGS)
 1948078 PROTEIN
 1364406 PROTEINS
 2269874 PROTEIN
 (PROTEIN OR PROTEINS)
 154312 BINDING PROTEIN
 (BINDING (W) PROTEIN)
 0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
 L1 380 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
 BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

 => s doxorubicin or adriamycin
 15810 DOXORUBICIN
 28 DOXORUBICINS
 15812 DOXORUBICIN
 (DOXORUBICIN OR DOXORUBICINS)
 10770 ADRIAMYCIN

16 ADRIAMYCINS
10772 ADRIAMYCIN
(ADRIAMYCIN OR ADRIAMYCINS)

L2 25686 DOXORUBICIN OR ADRIAMYCIN

=> a l2 and l1

A IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and l1

L3 2 L2 AND L1

=> d ibib

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:450309 CAPLUS

DOCUMENT NUMBER: 141:36901

TITLE: Limited role of N-terminal phosphoserine residues in the activation of transcription by p53

AUTHOR(S): Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna L.; Agarwal, Archana; Stanhope-Baker, Patricia; Williams, Bryan R. G.; Stark, George R.

CORPORATE SOURCE: Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

SOURCE: Oncogene (2004), 23(25), 4477-4487

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib 1-2

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:450309 CAPLUS

DOCUMENT NUMBER: 141:36901

TITLE: Limited role of N-terminal phosphoserine residues in the activation of transcription by p53

AUTHOR(S): Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna L.; Agarwal, Archana; Stanhope-Baker, Patricia; Williams, Bryan R. G.; Stark, George R.

CORPORATE SOURCE: Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

SOURCE: Oncogene (2004), 23(25), 4477-4487

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:797013 CAPLUS

DOCUMENT NUMBER: 139:286301

TITLE: Method of judging cardiotoxicity of anthracycline-type anticancer chemical therapeutic by detecting human H-FABP and reagent therefor

INVENTOR(S): Kitayama, Hitoshi; Ohkaru, Yasuhiko

PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003083486	A1	20031009	WO 2003-JP3924	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003220882	A1	20031013	AU 2003-220882	20030328
EP 1491896	A1	20041229	EP 2003-715565	20030328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005202513	A1	20050915	US 2004-509571	20040929
PRIORITY APPLN. INFO.:			JP 2002-93688	A 20020329
			WO 2003-JP3924	W 20030328
REFERENCE COUNT:		3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

=> s cancer? or tumor? or neoplas?

315544 CANCER?

452001 TUMOR?

474391 NEOPLAS?

L4 748872 CANCER? OR TUMOR? OR NEOPLAS?

=> s 14 and 11

L5 32 L4 AND L1

=> s 15 not py>2002

4707679 PY>2002

L6 8 L5 NOT PY>2002

=> s 16 and antibod?

479076 ANTIBOD?

L7 2 L6 AND ANTIBOD?

=> d ibib 1-2

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:376177 CAPLUS

DOCUMENT NUMBER: 133:248010

TITLE: Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags

AUTHOR(S): Hwang, David M.; Dempsey, Adam A.; Lee, Cheuk-Yu; Liew, Choong-Chin

CORPORATE SOURCE: Cardiac Gene Unit, Department of Laboratory Medicine and Pathobiology, Centre for Cardiovascular Research, Toronto Hospital, University of Toronto, Toronto, ON, M5G 1L5, Can.

SOURCE: Genomics (2000), 66(1), 1-14

CODEN: GNMCEP; ISSN: 0888-7543

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:682528 CAPLUS
DOCUMENT NUMBER: 129:299045
TITLE: Cloning and cDNA sequence of human fatty acid-binding
protein
INVENTOR(S): Hillman, Jennifer L.; Shah, Purvi
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845440	A1	19981015	WO 1998-US7084	19980408
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868942	A	19981030	AU 1998-68942	19980408
PRIORITY APPLN. INFO.:			US 1997-825783	A2 19970408
			WO 1998-US7084	W 19980408
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> d kwic 2

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . polynucleotides which identify and encode Hu-FABP. Nucleic acids
encoding Hu-FABP were first identified in Incyte clone 2581906 from a
kidney tumor tissue cDNA library through a computer-generated
search for amino acid sequence alignments; a consensus sequence was
derived from overlapping and/or. . . acids in length and chemical and
structural homol. with FABP from chick retina, B-FABP from rat and mouse
brain, and H-FABP from mouse and human heart.
Northern anal. shows the most abundant expression of Hu-FABP in fetal
brain, which suggests a developmental role for this mol. In adults,
Hu-FABP is found primarily in cancer-associated tissues,
particularly, brain, kidney, and breast. The invention also provides
expression vectors, host cells, antibodies and antagonists. The
invention also provides methods for the prevention and treatment of
diseases associated with expression of Hu-FABP, as. . .
IT Antibodies
Probes (nucleic acid)
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical
study); BIOL (Biological study); USES (Uses)
(cloning and cDNA sequence of human fatty acid-binding protein)

=> file pctfull
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
59.03	59.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.75

-0.75

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 19 DEC 2006 <20061219/UP>
MOST RECENT UPDATE WEEK: 200650 <200650/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or
(heart type factty acid () binding protein)

485934 H

291 FABP

51 FABPS

307 FABP

(FABP OR FABPS)

45 H-FABP

(H(W)FABP)

8 HFABP

485934 H

291 FABP

51 FABPS

307 FABP

(FABP OR FABPS)

45 H (W) FABP

64305 HEART

4368 HEARTS

65049 HEART

(HEART OR HEARTS)

651740 TYPE

384590 TYPES

710359 TYPE

(TYPE OR TYPES)

75579 FATTY

2 FATTIES

75580 FATTY

(FATTY OR FATTIES)

286591 ACID

191691 ACIDS

297259 ACID

(ACID OR ACIDS)

138670 BINDING

2428 BINDINGS

139156 BINDING

(BINDING OR BINDINGS)

144350 PROTEIN

122052 PROTEINS

159658 PROTEIN

(PROTEIN OR PROTEINS)

18 HEART-TYPE FATTY ACID BINDING PROTEIN

(HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)

64305 HEART

4368 HEARTS

65049 HEART

(HEART OR HEARTS)

651740 TYPE

384590 TYPES
 710359 TYPE
 (TYPE OR TYPES)
 0 FACTTY
 286591 ACID
 191691 ACIDS
 297259 ACID
 (ACID OR ACIDS)
 0 HEART TYPE FACTTY ACID
 (HEART(W) TYPE(W) FACTTY(W) ACID)
 138670 BINDING
 2428 BINDINGS
 139156 BINDING
 (BINDING OR BINDINGS)
 144350 PROTEIN
 122052 PROTEINS
 159658 PROTEIN
 (PROTEIN OR PROTEINS)
 31430 BINDING PROTEIN
 (BINDING(W) PROTEIN)
 0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
 L8 57 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
 BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s 18 and antibod?
 93871 ANTIBOD?

L9 41 L8 AND ANTIBOD?

=> s 19 and doxorubicin or daunomycin or anthracyclin?

 1 DOXORUCICIN
 3555 DAUNOMYCIN
 22 DAUNOMYCINS
 3565 DAUNOMYCIN
 (DAUNOMYCIN OR DAUNOMYCINS)
 4401 ANTHRACYCLIN?
 L10 6166 L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?

=> s 19 and (doxorubicin or daunomycin or anthracyclin?)

 1 DOXORUCICIN
 3555 DAUNOMYCIN
 22 DAUNOMYCINS
 3565 DAUNOMYCIN
 (DAUNOMYCIN OR DAUNOMYCINS)
 4401 ANTHRACYCLIN?
 L11 2 L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> d ibib 1-2

L11 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2006131928 PCTFULL ED 20061219 EW 200650
 TITLE (ENGLISH): NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS
 AND METHODS OF USE THEREOF FOR DIAGNOSIS
 TITLE (FRENCH): NOUVELLES SEQUENCES DE NUCLEOTIDES ET D'ACIDES AMINES,
 LEURS DOSAGES ET METHODES D'UTILISATION EN VUE DU
 DIAGNOSTIC
 INVENTOR(S): SAMEAH-GREENWALD, Shirley, 33/7 Arlozorov Street, 44453
 Kfar-saba, IL;
 NOVIK, Amit, 31 Hasayfan Street, 40600 Tel-mond, IL;
 WALLACH, Shira, 40 Bnei Brit Street, 45265
 Hod-hasharon, IL;
 POLLOCK, Sarah, 16/2 Hoshea Street, 63506 Tel-aviv, IL;
 BAZAK, Lily, 46 Raynes Street, 53461 Givatayim, IL;
 TSYPKIN, Elena, 105/7 Even Gvirol Street, 64046
 Tel-aviv, IL;
 COJOCARU, Gad, S., 41/7 Hasayfan Street, 47248

Ramat-hasharon, IL;
 SELLA-TAVOR, Osnat, 18 Kfar Kish, 19330 Kfar Kish, IL
 PATENT ASSIGNEE(S): COMPUGEN LTD., 72 Pinchas Rosen Street, 69512 Tel Aviv, IL
 AGENT: WEBB, Cynthia et al.\$, Webb & Associates, P.O. Box 2189, 76121 Rehovot\$, IL
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2006131928	A2	20061214
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW		
RW (ARIPO):	BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2006-IL676 A 20060608		
PRIORITY INFO.:	US 2005-60688320 20050608		
	US 2005-60699427 20050715		
	US 2005-60704414 20050802		

L11 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2006026785 PCTFULL ED 20060403 EW 200610
 TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR MODULATING PGC-1a TO TREAT
 NEUROLOGICAL DISEASES AND DISORDERS
 TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE MODULATION DE PGC-1\$G(A)
 POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES
 NEUROLOGIQUES
 INVENTOR(S): LIN, Jiandie, 79 Chestnut Street, Apt.#1, Brookline, MA
 02445, US;
 SPIEGELMAN, Bruce, M., 271 Waban Avenue, Waban, MA
 02168, US
 PATENT ASSIGNEE(S): DANA-FARBER CANCER INSTITUTE, INC., 44 Binney Street,
 Boston, MA 02115-6084, US
 AGENT: SMITH, DeAnn, F. et al.\$, Patent Group, Foley Hoag LLP,
 Seaport World Trade Center West, 155 Seaport Blvd.,
 Boston, MA 02210; 02210\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2006026785	A2	20060309
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW		
RW (ARIPO):	BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		

APPLICATION INFO.: WO 2005-US31715 A 20050906
PRIORITY INFO.: US 2004-60607412 20040903

=> d his

(FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

L1 380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2 25686 S DOXORUBICIN OR ADRIAMYCIN
L3 2 S L2 AND L1
L4 748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5 32 S L4 AND L1
L6 8 S L5 NOT PY>2002
L7 2 S L6 AND ANTIBOD?

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006

L8 57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9 41 S L8 AND ANTIBOD?
L10 6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11 2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> s l9 not py>2002

481204 PY>2002

L12 12 L9 NOT PY>2002

=> s l12 and kit

81427 KIT

38881 KITS

87623 KIT

(KIT OR KITS)

L13 9 L12 AND KIT

=> s l8/ab

16209 H/AB

16 FABP/AB

1 FABPS/AB

17 FABP/AB

((FABP OR FABPS)/AB)

6 H-FABP/AB

((H(W) FABP)/AB)

0 HFABP/AB

16209 H/AB

16 FABP/AB

1 FABPS/AB

17 FABP/AB

((FABP OR FABPS)/AB)

6 H/AB (W) FABP/AB

5057 HEART/AB

33 HEARTS/AB

5073 HEART/AB

((HEART OR HEARTS)/AB)

87567 TYPE/AB

15286 TYPES/AB

98263 TYPE/AB

((TYPE OR TYPES)/AB)

6744 FATTY/AB

63647 ACID/AB

17172 ACIDS/AB

73135 ACID/AB

((ACID OR ACIDS)/AB)

16377 BINDING/AB

141 BINDINGS/AB

16461 BINDING/AB

```

      ((BINDING OR BINDINGS)/AB)
25316 PROTEIN/AB
14190 PROTEINS/AB
34108 PROTEIN/AB
      ((PROTEIN OR PROTEINS)/AB)
      0 HEART-TYPE FATTY ACID BINDING PROTEIN/AB
      ((HEART(W) TYPE(W) FATTY(W) ACID(W) BINDING(W) PROTEIN)/AB)
5057 HEART/AB
      33 HEARTS/AB
5073 HEART/AB
      ((HEART OR HEARTS)/AB)
87567 TYPE/AB
15286 TYPES/AB
98263 TYPE/AB
      ((TYPE OR TYPES)/AB)
      0 FACTTY/AB
63647 ACID/AB
17172 ACIDS/AB
73135 ACID/AB
      ((ACID OR ACIDS)/AB)
      0 HEART TYPE FACTTY ACID/AB
      ((HEART(W) TYPE(W) FACTTY(W) ACID)/AB)
16377 BINDING/AB
      141 BINDINGS/AB
16461 BINDING/AB
      ((BINDING OR BINDINGS)/AB)
25316 PROTEIN/AB
14190 PROTEINS/AB
34108 PROTEIN/AB
      ((PROTEIN OR PROTEINS)/AB)
      1255 BINDING PROTEIN/AB
      ((BINDING(W) PROTEIN)/AB)
      0 HEART TYPE FACTTY ACID/AB (W) BINDING PROTEIN/AB
L14      6 (H-FABP/AB OR (HFABP/AB) OR (H/AB (W) FABP/AB) OR (HEART-TYPE
      FATTY ACID BINDING PROTEIN/AB) OR (HEART TYPE FACTTY ACID/AB
      (W) BINDING PROTEIN/AB))

```

=> s 18/clm

```

190960 H/CLM
      60 FABP/CLM
      14 H-FABP/CLM
      ((H(W) FABP)/CLM)
      1 HFABP/CLM
190960 H/CLM
      60 FABP/CLM
      14 H/CLM (W) FABP/CLM
11386 HEART/CLM
104803 TYPE/CLM
14215 FATTY/CLM
136223 ACID/CLM
40435 BINDING/CLM
52853 PROTEIN/CLM
      6 HEART-TYPE FATTY ACID BINDING PROTEIN/CLM
      ((HEART(W) TYPE(W) FATTY(W) ACID(W) BINDING(W) PROTEIN)/CLM)
11386 HEART/CLM
104803 TYPE/CLM
      0 FACTTY/CLM
136223 ACID/CLM
      0 HEART TYPE FACTTY ACID/CLM
      ((HEART(W) TYPE(W) FACTTY(W) ACID)/CLM)
40435 BINDING/CLM
52853 PROTEIN/CLM
3331 BINDING PROTEIN/CLM
      ((BINDING(W) PROTEIN)/CLM)
      0 HEART TYPE FACTTY ACID/CLM (W) BINDING PROTEIN/CLM

```

L15 17 (H-FABP/CLM OR (HFABP/CLM) OR (H/CLM (W) FABP/CLM) OR (HEART-TYP
E FATTY ACID BINDING PROTEIN/CLM) OR (HEART TYPE FACTTY ACID/CLM
(W) BINDING PROTEIN/CLM))

=> s l15 or l14

L16 19 L15 OR L14

=> d his

(FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

L1 380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2 25686 S DOXORUBICIN OR ADRIAMYCIN
L3 2 S L2 AND L1
L4 748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5 32 S L4 AND L1
L6 8 S L5 NOT PY>2002
L7 2 S L6 AND ANTIBOD?

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006

L8 57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9 41 S L8 AND ANTIBOD?
L10 6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11 2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
L12 12 S L9 NOT PY>2002
L13 9 S L12 AND KIT
L14 6 S L8/AB
L15 17 S L8/CLM
L16 19 S L15 OR L14

=> s l16 and l13

L17 3 L16 AND L13

=> d ibib 1-3

L17 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002089657 PCTFULL ED 20021121 EW 200246
TITLE (ENGLISH): DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND
METHODS OF USE THEREOF
TITLE (FRENCH): MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS
ET LEURS METHODES D'UTILISATION
INVENTOR(S): VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US];
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US];
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US];
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US]
PATENT ASSIGNEE(S): BIOSITE, INC., 11030 Roselle Street, San Diego, CA
92121, US [US, US], for all designates States except
US;
VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US], for US only;
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US], for US only;
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US], for US only;
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US], for US only
AGENT: WARBURG, Richard, J.\$, Foley & Lardner, P.O. Box 80278,
San Diego, CA 92138-0278\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002089657	A2	20021114

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US14219 A 20020504

PRIORITY INFO.: US 2001-60/288,871 20010504

US 2001-60/315,642 20010828

L17 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 2001067108 PCTFULL

no bibliographic data available - please use FPI for PI information

DESIGNATED STATES

L17 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 1997035878 PCTFULL ED 20020514

TITLE (ENGLISH): THE PORCINE HEART FATTY ACID-BINDING PROTEIN ENCODING
GENE AND METHODS TO IDENTIFY POLYMORPHISMS ASSOCIATED
WITH BODY WEIGHT

TITLE (FRENCH): GENE CODANT UNE PROTEINE SE LIANT A UN ACIDE GRAS DU
COEUR DE PORC ET PROCEDE D'IDENTIFICATION DES
CARACTERISTIQUES DU POLYMORPHISME RESPONSABLES DU POIDS
DU CORPS

INVENTOR(S): GERBENS, Frans

PATENT ASSIGNEE(S): DALLAND B.V.;

PROVA B.V.;

STAMBOEK ZUID B.V.;

NOORD NEDERLANDS VARKENSSTAMBOEK B.V.;

INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID (ID-DLO);

GERBENS, Frans

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9735878	A2	19971002

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ
UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG

APPLICATION INFO.: WO 1997-NL157 A 19970327

PRIORITY INFO.: NL 1996-96200855.3 19960328

=> d ibib kwic 1

L17 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 2002089657 PCTFULL ED 20021121 EW 200246

TITLE (ENGLISH): DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND
METHODS OF USE THEREOF

TITLE (FRENCH): MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS
ET LEURS METHODES D'UTILISATION

INVENTOR(S): VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US];
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US];
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US];
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US]

PATENT ASSIGNEE(S): BIOSITE, INC., 11030 Roselle Street, San Diego, CA
92121, US [US, US], for all designates States except
US;
VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
92025, US [US, US], for US only;
DAHLEN, Jeffrey, R., 10555 Kimmerton Road, San Diego,
CA 92126, US [US, US], for US only;
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
92121, US [US, US], for US only;
BUECHLER, Kenneth, F., 12523 Manifesto Place, San
Diego, CA 92130, US [US, US], for US only

AGENT: WARBURG, Richard, J.\$, Foley & Lardner, P.O. Box 80278,
San Diego, CA 92138-0278\$, US

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2002089657	A2	20021114
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US14219	A	20020504
PRIORITY INFO.:	US 2001-60/288,871		20010504
	US 2001-60/315,642		20010828

DETD . . . annexin V, B-type natriuretic peptide, P-enolase,
cardiac troponin I (free and/or complexed), cardiac troponin T (free
and/or coinplexed),
creatine kinase-MB, glycogen phosphorylase-BB, heart-
type fatty acid binding
protein,
phosphoglyceric acid mutase-MB, and S-100ao. These specific markers are
described
in detail hereinafter.

[0038] In a further aspect, the invention relates to kits for
determining the diagnosis
or prognosis of a patient. These kits preferably comprise
devices and reagents for
measuring one or more marker levels in a patient sample, and
instructions for
performing the assay. Optionally, the kits may contain one or
more means for
converting marker level(s) to a prognosis. Such kits
preferably contain sufficient

reagents to perform one or more such determinations.

al., Ain. J. Einerg. Med 17:225-229, 1999). This apparent non-specificity may be related to the quality and specificity of the antibodies used in the immunoassay. cTnI is released into the bloodstream following cardiac cell death. The plasma concentration of cTnI in patients with.

[00591 Heart-type fatty acid binding protein (H-FABP) is a cytosolic 15 kDa lipid-binding protein involved in lipid metabolism. Heart-type FABP antigen is found not only in heart tissue,. . . and Maatman, R.G., Prog. Lipid Res. 34:17-52,1995). The normal plasma concentration of FABP is < 6 ng/ml (400 pM). The plasma H-FABP concentration is elevated in patients with AMI and unstable angina (Ishii, J. et al., Clin. Chem. 43:1372-1378, 1997; Tsuji, R. et al., Int. J Cardiol. 41:209-217, 1993). Furthermore, H-FABP may be useful in estimating infarct size in patients with AMI (Glatz, U. et al., Br.

Heart J. 71:13 5 -140, 1994). Myocardial tissue as a source of H-FABP can be confirmed by determining the ratio of myoglobin/FABP (grams/grams). A ratio of approximately 5 indicates that FABP is of myocardial origin,. . . while a higher ratio indicates skeletal muscle sources (Van Nieuwenhoven, F.A. et al., Circulation 92:2848-2854, 1995). Because of the presence of H-FABP in skeletal muscle, kidney and brain, elevations in the plasma H-FABP concentration may be associated with skeletal muscle injury, renal disease, or stroke. H-FABP is released into the bloodstream following cardiac tissue necrosis. The plasma H-FABP concentration can be significantly elevated 1-2 hours after the onset of chest pain, earlier than CK-MB and myoglobin (Tsuji, R. et al.,. . .

Additionally, H-FABP is rapidly cleared from the bloodstream, and plasma concentrations return to baseline after 24 hours after AMI onset (Glatz, J.F. et. . .

mediate crosslinking of platelets to vascular subendothelium, respectively. Measurement of any of these vWF forms, when used in an assay that employs antibodies specific for the protease cleavage domain may allow assays to be used to determine the circulating concentration of various vWF forms in.

TpPTM may also be useful in determining the severity of unstable angina. American Biogenetic Sciences, Inc. instructs users of the TpPTM ELISA assay kit to collect blood using citrate as an anticoagulant, and they recommend against using EDTA. The effect of the anticoagulant used during. . .

in the art (for example, the measurement of marker RNA levels). The presence or amount of a marker is generally determined using antibodies specific for each marker and detecting specific binding. Any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like. Specific immunological binding of the antibody to the marker can be detected directly or indirectly. Direct labels include fluorescent or luminescent tags, metals, dyes, radionuclides, and the like, attached to the antibody. Indirect labels include various enzymes well known in the art, such as alkaline phosphatase, horseradish peroxidase and the like.

[00981 The use of immobilized antibodies specific for the markers is also contemplated by the present invention. The antibodies could be immobilized onto a variety of solid supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate. . . . of a solid substrate material (such as plastic, nylon, paper), and the like. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip
55
could then be dipped into the test sample and then processed quickly through. . . .

[01021 In another embodiment, the present invention provides a kit for the analysis of markers. Such a kit preferably comprises devices and reagents for the analysis of at least one test sample and instructions for performing the assay. Optionally the kits may contain one or more means for converting a marker level to a diagnosis or prognosis of
I 0 the patient.

[01041 Markers were measured using standard immunoassay techniques. These techniques involved the use of antibodies to specifically bind the protein targets. A monoclonal antibody directed against a selected marker was biotinylated using N-hydroxysuccinimide biotin (NHS-biotin) at a ratio of about 5 NHS-biotin moieties per antibody. The antibody-biotin conjugate was then added to wells of a standard avidin 384 well microtiter plate, and antibody conjugate not bound to the plate was removed. This formed the anti-marker in the microtiter plate. Another monoclonal
57

antibody directed against the same marker was conjugated to alkaline phosphatase using succinimidyl 4-[N-maleimidomethyl]-cyclohexane-1-carboxylate (SMCC) and N-succinimidyl 3-[2-pyridyldithio]propionate (SPDP) (Pierce, . . .

[01051 Immunoassays were performed on a TECAN Genesis RSP 200/8 Workstation. Biotinylated antibodies were pipetted into microtiter plate wells previously coated with avidin and incubated for 60 min. The solution containing unbound antibody was removed, and the cells were washed with a wash buffer, consisting of 20 mM borate (pH 7.42) containing 150 mM NaCl, and incubated for 60 min. The sample was then removed and the wells were washed with a wash buffer. The antibody-alkaline phosphatase conjugate was then added to the wells and incubated for an additional 60 min, after which time, the antibody conjugate was removed and the wells were washed with a wash buffer. A substrate, (AttoPhos), Promega, Madison, WI) was added to. . .

[01061 Assays for BNP were performed using murine anti-BNP monoclonal antibody 106.3 obtained from Scios Incorporated (Sunnyvale, CA). The hybridoma cell line secreting mAb 106.3 was generated from a fusion between FOXP-3 cells and spleen cells from a Balb/c mouse immunized with human BNP 1-32 conjugated to BSA. A second murine anti-BNP antibody was produced by Biosite Incorporated (San Diego, CA) by antibody phage display as described previously (US Patent No.

[01071 Assays for MMP-9 were performed using murine anti-MMP-9 antibodies generated by Biosite Incorporated using phage display and recombinant protein expression as described previously (US Patent No. 6,057,098). Commercially available MMP-9 antigen was used for assay standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The immunogen used for antibody production was prepared by Biosite Incorporated. PCR primers were made corresponding to sequence at the 5'-end of human MMP-9 and the coding. . .

of these clones (A4MMP9peak12) was verified at MacConnell Research (San Diego, CA) by the dideoxy chain termination method using a Sequatherm sequencing

kit (Epicenter Technologies, Madison, WI), oligonucleotide primers C, 5'-TTCTCAAGCCTCAGACAGTG - Y (SEQ ID NO:3), and D, 5'-CCTGGATGCAGGCTACTCTAG - Y (SEQ ID NO:4), that. . . suitable for transfection and the subsequent expression and purification of human MMP-9 was prepared from clone MMP9peak12.2 using an EndoFree Plasmid Mega Kit as per manufacturer's recommendations (Qiagen, Valencia, CA). HEK 293 (Peak) cells were expanded into a T-75 flask from a 1ml frozen vial. . .

[01081 Assays for NUVIP-9 were performed using murine anti-XIMP-9 antibodies generated at Biosite Incorporated, using phage display and recombinant protein expression techniques. Commercially available NIMP-9 antigen was used for assay

standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The concentration of MMP-9 was quantified by detecting the binding of alkaline phosphatase-conjugated antibody. The minimal detectable concentration for the assay was 0.3 ng/mL and the upper end of the reportable range was 2000 ng/mL.

[01091 Assays for Thrombus precursor Protein (TpPTM) were performed using reagents obtained from American Biogenetic Sciences, Inc., Columbia,]M-Two murine monoclonal antibodies that recognize different epitopes on the soluble fibrin polymer were employed for the assay. The assay was calibrated using TpPTM supplied by.

[01101 Assays for Monocyte Chemotactic protein-1 (MCP-1) were performed using antibodies developed at Biosite. The assays were developed in an immunometric (sandwich) format. The assays were calibrated with an in-house MCP- I.

various forms of troponin I (TIC complex and total TnI) were performed using a commercially available goat anti-TnI for capture and antibodies developed at Biosite as the enzyme-labeled conjugates. The assays were calibrated with in-house TIC complex and TnI reference solutions. The minimal detectable concentration.

[0112] Assays for fatty acid binding protein (FABP) were performed using commercially available monoclonal antibodies and a commercially available FABP antigen. The minimal detectable concentration was 6 ng/ml and the upper end of the reportable range was.

in the example above. Alternative or additional markers of myocardial injury include annexin V, BNP and/or BNP-related peptides, P-enolase, creatine kinase-MB, glycogen phosphorylase-BB, heart-type fatty acid binding protein, phosphoglyceric acid mutase-MB, and S-100ao.

MMP-9 assay

[01241 Assays for MAV-9 were performed using murine anti-MMP-9 antibodies generated at Biosite Incorporated, using phage display and recombinant protein expression techniques. Commercially available NEVIP-9 antigen was used for assay standardization (Calbiochem-Novabiochem Corporation,. . . on a robotic high-throughput platform (TECAN Genesis RSP 200/8). The concentration of MMP-9 was quantified by detecting the binding of alkaline phosphatase-conjugated antibody. All samples were run in duplicate. The minimal detectable concentration for the assay was 3.0 ng/mL and the upper end of the.

strategies can include, e.g., delivery of antisense compositions in order to disrupt the synthesis of MMP-9; delivery of receptor-based therapeutics (e.g., an antibody composition directed to MMP-9 or a fragment thereof); and/or delivery of small molecule therapeutics (e.g., heparin can decrease MMP-9 synthesis, tetracycline antibiotics. . .

CLMEN. . . myocardial injury is selected from the group consisting of annexin V, B-type natriuretic peptide, enolase, cardiac troponin I, creatine kinase-MB, glycogen phosphorylase-BB, heart-type fatty acid binding protein, phosphoglyceric acid mutase-MB, and S- 1 00ao.

=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or (daunomycin or daunorubicin)

188048 ANTI
185 ANTIS
188087 ANTI
(ANTI OR ANTIS)
79510 CANCER
30806 CANCERS
81924 CANCER
(CANCER OR CANCERS)
12783 ANTI (W) CANCER
35587 CHEMOTHE?
4414 ANTHRACYCL?
18658 DOX?
5135 ADRIAMYCIN
17 ADRIAMYCINS
5142 ADRIAMYCIN
(ADRIAMYCIN OR ADRIAMYCINS)
3555 DAUNOMYCIN
22 DAUNOMYCINS
3565 DAUNOMYCIN
(DAUNOMYCIN OR DAUNOMYCINS)
6682 DAUNORUBICIN
12 DAUNORUBICINS
6684 DAUNORUBICIN
(DAUNORUBICIN OR DAUNORUBICINS)

L18 49281 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> d his

(FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006

L1 380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2 25686 S DOXORUBICIN OR ADRIAMYCIN
L3 2 S L2 AND L1
L4 748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5 32 S L4 AND L1
L6 8 S L5 NOT PY>2002
L7 2 S L6 AND ANTIBOD?

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006

L8 57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9 41 S L8 AND ANTIBOD?
L10 6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?

L11 2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
 L12 12 S L9 NOT PY>2002
 L13 9 S L12 AND KIT
 L14 6 S L8/AB
 L15 17 S L8/CLM
 L16 19 S L15 OR L14
 L17 3 S L16 AND L13
 L18 49281 S (ANTI () CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR

=> s 118 and 117

L19 0 L18 AND L17

=> s 119 and 19

L20 0 L19 AND L9

=> s 118 and 19

L21 8 L18 AND L9

=> s 121 not py>2002

481204 PY>2002

L22 3 L21 NOT PY>2002

=> d ibib 1-3

L22 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2001068851 PCTFULL ED 20020822
 TITLE (ENGLISH): POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
 TITLE (FRENCH): NOUVEAUX POLYPEPTIDES ET ACIDES NUCLEIQUES LES CODANT
 INVENTOR(S): PADIGARU, Muralidhara;

VERNET, Corine, A., M.;
 FERNANDES, Elma;
 SHIMKETS, Richard, A.;
 SPADERNA, Steven, K.;
 MAJUMDER, Kumud;
 LI, Li

PATENT ASSIGNEE(S): CURAGEN CORPORATION;
 PADIGARU, Muralidhara;
 VERNET, Corine, A., M.;
 FERNANDES, Elma;
 SHIMKETS, Richard, A.;
 SPADERNA, Steven, K.;
 MAJUMDER, Kumud;

LI, Li

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001068851	A2	20010920

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
 IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
 MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
 SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
 CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
 CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US7735 A 20010312

PRIORITY INFO.:

US 2000-60/188,316 20000310
 US 2000-60/188,277 20000310
 US 2000-60/189,139 20000314
 US 2000-60/189,140 20000314
 US 2000-60/190,401 20000317
 US 2000-60/190,231 20000317

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2000033083 PCTFULL ED 20020515
 TITLE (ENGLISH): DIAGNOSIS OF STAGE OR AGGRESSIVENESS OF CANCER
 TITLE (FRENCH): DIAGNOSTIC DE LA PHASE D'EVOLUTION OU DE L'AGRESSIVITE
 DE CANCERS
 INVENTOR(S): JETT, Marti;
 DAS, Rina;
 NEILL, Roger
 PATENT ASSIGNEE(S): WRAIR;
 JETT, Marti;
 DAS, Rina;
 NEILL, Roger
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000033083	A1	20000608

DESIGNATED STATES
 W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
 KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
 GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
 ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US28314 A 19991130
 PRIORITY INFO.: US 1998-60/110,484 19981201

L22 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1997035028 PCTFULL ED 20020514
 TITLE (ENGLISH): CYTOSTATIN III
 TITLE (FRENCH): CYTOSTATINE III
 INVENTOR(S): NI, Jian;
 YU, Guo-Liang;
 GENTZ, Reiner, L.
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
 NI, Jian;
 YU, Guo-Liang;
 GENTZ, Reiner, L.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9735028	A1	19970925

DESIGNATED STATES
 W:

AM AU BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LT
 LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM UA US UZ VN
 AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1996-US3697 A 19960319

=> d kwic 2

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD BACKGROUND OF THE INVENTION

Although screening mammography and the increased use of breast
 conserving surgery
 and adjuvant chemotherapy have improved the quality of life
 and prolonged survival for women
 with breast cancer, additional therapeutic strategies are needed to
 combat.

Modulation of mitogenesis by liver fatty acid binding protein, Cancer Metastasis Rev 13:317-36, 1994.). In contrast, MDGI (H-FABP) appears only in normal and not tumor mammary cells (Grosse R, Boehmer FD, Langen P, Kurtz A, Lehmann W, Mieth M. . . .

types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1081:1-24, 1991). L-FABP exhibits different lipid binding characteristics from that of A-FABP or H-FABP. L-FABP transfected into rat hepatoma cells also mediates cell induction by carcinogenic peroxisome proliferators (Khan SH and Sorof S.: Liver. . . .

L-FABP is elevated significantly in metastatic or regenerating liver vs normal liver. This is in stark contrast to H-FABP, also known as mammary derived growth inhibitor (MDGI). It is present only in normal lactating breast, and completely disappears in mammary. . . . performed a similar study (to the eicosanoid generation in hepatic cells) in MCF-7 cells transfected with a clone of the MDGI (H-FABP) gene or vector alone. The inventors also have examined these pairs of cells to determine cell cycle pattern changes related to MDGI. . . .

identification of markers that define their degree of differentiation. Cancer Res 57:4111-7, 1997.). Although FABPs are intracellular proteins, H-FABP has been detected in elevated levels in plasma and urine of patients suffering from myocardial infarction, (Sohmiya K, Tanaka T, Tsuji R, . . . III had 37% reduction and grade IV had no A-FABP expression. A-FABP may act as a growth inhibitor similar to the MDGI (H-FABP) protein in breast cancer and loss of A-FABP expression may serve as a prognostic marker for aggressive bladder cancer.

These results suggests that A-FAIBP and E-FA_BP may act as a tumor suppressors in prostate cells similar to MDGI (H-FABP) in MCF-7 cells (Huynh H, Alpert L and Pollak M..

fluid but normal prostate cells did not secrete measurable amounts of this protein. In addition, previous studies have shown that a) H-FABP was secreted into plasma during severe myocardial infarction and b) E-FABP was decreased in urine in bladder cancer.

The inventors have shown that the pattern of B-, L-, I-FABPs, taken together, along with decreases in A-, E-, and H-FABPs, are indicative of the relative aggressiveness of the cancer. The pattern of FABI's provide potential markers to help patients choose a.

Furthermore, the normal cell-associated FABPs (E-, A-, and H-FABPs) were decreased in tumor cells (3 -II fold). In patient specimens of normal and tumor prostate tissue, these patterns were repeated, in. . . .

sample was used by doing a concentration curve for each sample. These biotin labeled PCR products were quantitated using streptavidin coated antibodies (Streptavidin has very high affinity for Biotin) which was linked to HRP (Horse Radish Peroxidase) or a fluorescent tag that was used. . . .

(Bradford method, Bio Rad, CA) and then ELISA was performed to evaluate the levels of the various FABI's by using specific antibodies to each of the different types of FABPs. Antibodies such as heart FABP antibody and Liver-FABP antibody obtained from Research Diagnostics, Inc., Pleasant Hill Road, Flanders, NJ 07836 were used in these tests. However, antibodies for the remaining FABPS can also be developed and used. The levels of these proteins were correlated to the stages of. . . .

4) epidermis or psoriasis-associated (E-FABP), 5) liver (L-FABP), 6) intestine (I-FABP), and 7) myelin or P2 (P2-FABP). As a group A-FABP, H-FABP, B-FABP, and E-FABP in humans share between 50-65% protein sequence homology and contain a tyrosine near residue 20 that can be. . . .

MCF-7 ADR cells. This allows the use of this drug when the patient starts showing drug resistance to the commonly used chemotherapeutic drugs. This drug is nontoxic to mice when tested for any change in body weight or by necropsy studies. This drug is also not toxic to human bone marrow cells, which are effected the most during chemotherapy.

inhibitors of eicosanoid metabolism on the growth of breast cancer cells. Inhibitors contemplated are those currently used in clinical situations such as doxorubicin, 5FU, vinca alkaloids, adriamycin as well as lipoxygenase inhibitors. The HPA drug can be given simultaneously with or can be given followed by exposing the cancerous. . . . to block the growth of the cancerous cells and change the FABP profile to a normal cell FABP profile. Subsequent

27 applications of chemotherapeutic agents or inhibitor can be given in a lower amount than previous applications.

representing unique regions of each specific FABP. We will synthesize these peptides, attach them to a carrier molecule and generate specific antibodies for each of FABPs. These

30 antibodies are crucial for use in development of ELISA procedures to detect each of the specific FABI's in body fluids and, perhaps,. . . .

CLMEN. . . . 8 The method of claim 4, wherein said detecting comprises measuring the amount fatty acid binding proteins in the sample with antibodies and determining type of fatty acid binding protein in the sample by ELISA.

9 The method of claim 5, wherein said detecting comprises measuring the amount fatty

acid binding proteins in the sample with antibodies and determining type of fatty acid binding protein in the sample by ELISA.

10 The method of claim 8, wherein said antibodies are specific to at least one protein selected from the group consisting of Liver-FABP, Intestinal-FABP, Adipose-FABP, CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

11 The method of claim 9, wherein said antibodies are specific to at least one protein selected from the group consisting of Liver-FABP, Intestinal-FABP, Adipose-FABP, CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

of-
a) detecting the amount of at least one fatty acid binding protein present in a sample of mammalian body fluid with antibodies specific to said fatty acid binding protein;
b) determining the difference in the amount of the at least one fatty acid binding protein.

the
steps of-
a) detecting the amount of at least one fatty acid binding protein present in a sample of mammalian tissue with antibodies specific to said fatty acid binding protein;
39
b) determining the difference in the amount of the at least one fatty acid.

cell
FABP profile to a normal cell FABP profile; and
b) exposing the cancer cells to a first predetermined amount of a chemotherapeutic agent or cancer inhibitor sufficient to block the growth of the cells.

21 The method of claim 19, wherein said inhibitor is doxorubicin, 5FU, vinca alkaloids or lipoxxygenase inhibitors.

26 The method of inhibiting growth of cancer cells of claim 19, further comprising exposing the cancer cells to a chemotherapeutic agent or inhibitor a second time in a second lower amount than said first predetermined amount.

of breast or. prostate cancer cells of claim 19, wherein the method of inhibiting directed to breast cells and the known chemotherapeutic agent or drug is one of 5-flourouracil or adriamycin.

=> file dissab
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
33.07	92.31

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00

-0.75

FILE 'DISSABS' ENTERED AT 11:39:16 ON 19 DEC 2006

COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE COVERS 1861 TO 27 NOV 2006 (20061127/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)

59809 H
95 FABP
29 FABPS
102 FABP
(FABP OR FABPS)
13 H-FABP
(H(W) FABP)
1 HFABP
59809 H
95 FABP
29 FABPS
102 FABP
(FABP OR FABPS)
13 H (W) FABP
19262 HEART
1651 HEARTS
20021 HEART
(HEART OR HEARTS)
138410 TYPE
97741 TYPES
211295 TYPE
(TYPE OR TYPES)
7556 FATTY
1 FATTIES
7557 FATTY
(FATTY OR FATTIES)
68494 ACID
24901 ACIDS
80503 ACID
(ACID OR ACIDS)
49720 BINDING
166 BINDINGS
49793 BINDING
(BINDING OR BINDINGS)
80601 PROTEIN
44527 PROTEINS
93270 PROTEIN
(PROTEIN OR PROTEINS)
3 HEART-TYPE FATTY ACID BINDING PROTEIN
(HEART (W) TYPE (W) FATTY (W) ACID (W) BINDING (W) PROTEIN)
19262 HEART
1651 HEARTS
20021 HEART
(HEART OR HEARTS)
138410 TYPE
97741 TYPES
211295 TYPE

(TYPE OR TYPES)

0 FACTTY

68494 ACID

24901 ACIDS

80503 ACID

(ACID OR ACIDS)

0 HEART TYPE FACTTY ACID

(HEART(W) TYPE(W) FACTTY(W) ACID)

49720 BINDING

166 BINDINGS

49793 BINDING

(BINDING OR BINDINGS)

80601 PROTEIN

44527 PROTEINS

93270 PROTEIN

(PROTEIN OR PROTEINS)

7721 BINDING PROTEIN

(BINDING(W) PROTEIN)

0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN

L23 15 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s l23 and antibod?

19910 ANTIBOD?

L24 3 L23 AND ANTIBOD?

=> d ibib 1-3

L24 ANSWER 1 OF 3 DISSABS COPYRIGHT (C) 2006 ProQuest Information and
Learning Company; All Rights Reserved on STN

ACCESSION NUMBER: 2001:30986 DISSABS Order Number: AAI9991903

TITLE: Mechanisms of fatty acid transport and uptake by adipocyte
fatty acid-binding protein

AUTHOR: Liou, Heng-Ling [Ph.D.]; Storch, Judith [adviser]

CORPORATE SOURCE: Rutgers The State University of New Jersey - New Brunswick
(0190)

SOURCE: Dissertation Abstracts International, (2000) Vol. 61, No.
10B, p. 5242. Order No.: AAI9991903. 251 pages.
ISBN: 0-599-99576-9.

DOCUMENT TYPE: Dissertation

FILE SEGMENT: DAI

LANGUAGE: English

L24 ANSWER 2 OF 3 DISSABS COPYRIGHT (C) 2006 ProQuest Information and
Learning Company; All Rights Reserved on STN

ACCESSION NUMBER: 97:77250 DISSABS Order Number: AAR9800797

TITLE: STRUCTURE, FUNCTION AND DISTRIBUTION OF LIPID BINDING
PROTEINS IN MOUSE BRAIN (HEART FATTY ACID BINDING PROTEIN,
AGING)

AUTHOR: PU, LIXIA [PH.D.]; SCHROEDER, FRIEDHELM [advisor]

CORPORATE SOURCE: TEXAS A&M UNIVERSITY (0803)

SOURCE: Dissertation Abstracts International, (1997) Vol. 58, No.
7B, p. 3597. Order No.: AAR9800797. 147 pages.

DOCUMENT TYPE: Dissertation

FILE SEGMENT: DAI

LANGUAGE: English

ENTRY DATE: Entered STN: 19971124
Last Updated on STN: 19971124

L24 ANSWER 3 OF 3 DISSABS COPYRIGHT (C) 2006 ProQuest Information and
Learning Company; All Rights Reserved on STN

ACCESSION NUMBER: 94:22128 DISSABS Order Number: AARC349190 (not available
for sale by UMI)

TITLE: HETEROLOGOUS EXPRESSION OF THE BOVINE CARDIAC FATTY
ACID-BINDING PROTEIN (H-FABP) IN THE

YEAST YARROWIA LIPOLYTICA: BIOCHEMICAL AND PHYSIOLOGICAL
STUDIES
HETEROLOGE EXPRESSION DES FETTSÄURE-BINDENDEN PROTEINS AUS
RINDERHERZ (H-FABP) IN DER HEFE
YARROWIA LIPOLYTICA: BIOCHEMISCHE UND PHYSIOLOGISCHE
UNTERSUCHUNGEN

AUTHOR: BAUER, RONALD EDUARD [DR. TECHN.]
CORPORATE SOURCE: TECHNISCHE UNIVERSITÄT GRAZ (AUSTRIA) (5800)
SOURCE: Dissertation Abstracts International, (1993) Vol. 55, No.
2C, p. 449. Order No.: AARC349190 (not available for sale
by UMI). UNIVERSITY LIBRARY, TECHNISCHE UNIVERSITÄT GRAZ,
TECHNIKERSTRASSE 4, A-8010 GRAZ, AUSTRIA.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: German
ENTRY DATE: Entered STN: 19940607
Last Updated on STN: 19940607

=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or
(daunomycin or daunorubicin)

27176 ANTI
10 ANTIS
27182 ANTI
(ANTI OR ANTIS)
15632 CANCER
2379 CANCERS
16412 CANCER
(CANCER OR CANCERS)
488 ANTI (W) CANCER
2780 CHEMOTHE?
247 ANTHRACYCL?
825 DOX?
257 ADRIAMYCIN
92 DAUNOMYCIN
1 DAUNOMYCINS
92 DAUNOMYCIN
(DAUNOMYCIN OR DAUNOMYCINS)
78 DAUNORUBICIN

L25 4221 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR
ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> s 124 and 125

L26 0 L24 AND L25

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.57	96.88

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.75

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:40:15 ON 19 DEC 2006